Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment

[1]  H. Olsson,et al.  Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes , 2020, Cancers.

[2]  M. Czyz,et al.  Inhibitors of HSP90 in melanoma , 2019, Apoptosis.

[3]  A. Virós,et al.  Mechanisms of Drug Resistance in Melanoma. , 2017, Handbook of experimental pharmacology.

[4]  R. Dummer,et al.  Metastatic melanoma moves on: translational science in the era of personalized medicine , 2017, Cancer and Metastasis Reviews.

[5]  C. Garbe,et al.  MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. , 2017, European journal of cancer.

[6]  David J Beebe,et al.  Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement. , 2016, Pharmacology & therapeutics.

[7]  R. Scolyer,et al.  Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? , 2016, European journal of cancer.

[8]  K. Lewis,et al.  The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib , 2016, OncoTargets and therapy.

[9]  B. Maček,et al.  A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib , 2016, EBioMedicine.

[10]  M. Del Vecchio,et al.  Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade , 2015, Oncotarget.

[11]  Sabine Schmidt,et al.  A novel 96-well multielectrode array based impedimetric monitoring platform for comparative drug efficacy analysis on 2D and 3D brain tumor cultures. , 2015, Biosensors & bioelectronics.

[12]  A. Hauschild,et al.  Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  J. Simon,et al.  Direct chemosensitivity monitoring ex vivo on undissociated melanoma tumor tissue by impedance spectroscopy. , 2014, Cancer research.

[14]  G. Long,et al.  Systemic treatment for BRAF-mutant melanoma: where do we go next? , 2014, The Lancet. Oncology.

[15]  Samra Turajlic,et al.  BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling , 2014, Science Signaling.

[16]  H. Lilie,et al.  Comparative label-free monitoring of immunotoxin efficacy in 2D and 3D mamma carcinoma in vitro models by impedance spectroscopy. , 2014, Biosensors & bioelectronics.

[17]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[18]  Antoni Ribas,et al.  A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. , 2014, Cancer discovery.

[19]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[20]  L. Tentori,et al.  Challenging resistance mechanisms to therapies for metastatic melanoma. , 2013, Trends in pharmacological sciences.

[21]  Tianfeng Chen,et al.  Cyanidin reverses cisplatin-induced apoptosis in HK-2 proximal tubular cells through inhibition of ROS-mediated DNA damage and modulation of the ERK and AKT pathways. , 2013, Cancer letters.

[22]  F. Hodi,et al.  Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. , 2013, The oncologist.

[23]  K. Flaherty,et al.  Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Shelling,et al.  Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors , 2013, Front. Genet..

[25]  G. Pupo,et al.  Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma , 2013, Molecular Cancer Therapeutics.

[26]  N. Curtin,et al.  A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation , 2013, Cancer Chemotherapy and Pharmacology.

[27]  P. Ascierto,et al.  NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug , 2012, Journal of Translational Medicine.

[28]  P. Ascierto,et al.  NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug , 2012, Journal of Translational Medicine.

[29]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[30]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[31]  S. Kopetz,et al.  Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. , 2012, Cancer research.

[32]  X. Zhang,et al.  Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. , 2011, Cytokine.

[33]  J. Kirkwood,et al.  Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours , 2011, British Journal of Cancer.

[34]  A. Hauschild,et al.  The Oncologist® Academia–Pharma Intersect: Melanoma , 2022 .

[35]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[36]  B. Comin-Anduix,et al.  The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations , 2010, Clinical Cancer Research.

[37]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[38]  Marc Vidal,et al.  COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.

[39]  Sabine Schmidt,et al.  Real-time monitoring of relaxation and contractility of smooth muscle cells on a novel biohybrid chip. , 2010, Lab on a chip.

[40]  D. Heimbrook,et al.  RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. , 2010, Cancer research.

[41]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[42]  V. Sondak,et al.  Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  K Ann McKibbon,et al.  Current status and future prospects. , 2008, Health information and libraries journal.

[44]  A. Hauschild,et al.  In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group , 2006, Clinical Cancer Research.

[45]  Ssang-Goo Cho,et al.  Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. , 2006, Biochimica et biophysica acta.

[46]  T. Schlott,et al.  Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation , 2004, British Journal of Cancer.

[47]  D. Lev,et al.  Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  D. Lev,et al.  Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. , 2003, Molecular cancer therapeutics.

[49]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[50]  N. Holbrook,et al.  Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[51]  B. Mirakhur,et al.  Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma 2008/C13 cells. , 2000, International journal of oncology.

[52]  I. Cree,et al.  Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. , 1995, Cancer research.